Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07059000 · ClinicalTrials.gov registry record · Phase 3
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
A Phase 3 study of Chronic Primary Immune Thrombocytopenia (ITP), sponsored by Kedrion S.p.A..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT07059000: Recruiting Phase 3 study of Chronic Primary Immune Thrombocytopenia (ITP), sponsored by Kedrion S.p.A..
NCT07059000 is a Phase 3 study of Chronic Primary Immune Thrombocytopenia (ITP) that is actively recruiting participants, run by Kedrion S.p.A.. The registered enrollment target is 40 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07059000, a Phase 3 study of Chronic Primary Immune Thrombocytopenia (ITP), is actively recruiting participants, sponsored by Kedrion S.p.A..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
Primary Outcome
Assess the responder rate by measuring the platelet count increase according to the Response (R) definition and the absence of bleeding during the evaluation period
Conditions Studied
Interventions
- BIOLOGICAL Kedrion IVIG 10%
Study Locations (20)
Other
- Univerzitetski Klinicki Centar Srbije - Belgrade
- Klinicko-Bolnicki Centar Zemun - Belgrade
Madrid
- Complejo Hospitalario Ruber Juan Bravo - Madrid
- Hospital General Universitario Gregorio Marañón - Madrid
California
- University of Southern California - Los Angeles
North Carolina
- East Carolina University - Greenville
Prague
- Vseobecna Fakultni Nemocnice v Praze - Prague
South Moravian
- Fakultni Nemocnice Brno - Brno
Bavaria
- Onkologisches Zentrum Donauwörth Neudegger - Onkomedeor Onkologische Zentren - Donauwörth
Hesse
- Universitätsklinikum Frankfurt - Frankfurt am Main
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-08-13 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
What NCT07059000 shows while recruiting
NCT07059000 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Chronic Primary Immune Thrombocytopenia (ITP) appearing as the primary indexed condition, and to 1 intervention - of which Kedrion IVIG 10% is the first listed.
NCT07059000 names 20 study sites across 18 states, led by Other, Madrid, California.
Frequently Asked Questions
What is clinical trial NCT07059000 about?
NCT07059000 is a clinical study titled "A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)". The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP
What is the current status of trial NCT07059000?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2025-08-13. Estimated completion is 2026-08.
What conditions does trial NCT07059000 study?
This clinical trial studies the following conditions: Chronic Primary Immune Thrombocytopenia (ITP).
What interventions are being tested in trial NCT07059000?
The interventions under investigation include: Kedrion IVIG 10% (BIOLOGICAL).
Who is sponsoring clinical trial NCT07059000?
This trial is sponsored by Kedrion S.p.A., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07059000 being conducted?
This trial has 20 study locations across California, North Carolina, Prague, South Moravian, Bavaria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07059000's enrollment target sits among peer trials
40 1879th of 2000 higher than 103 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI